A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Clinical Trials
Hoffmann-La Roche
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
437 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University "mother Theresa" Hospital Center; Oncology Department
Tirana, Albania
- Cpmc; Service D'Oncologie Médicale
Algiers, Algeria
- Fundación Cenit Para la Investigación En Neurociencias
Buenos Aires, Argentina
- Hospital Britanico; Oncologia
Buenos Aires, Argentina
- Instituto de Investigaciones Clinicas Zarate
Zárate, Argentina
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
- St George Hospital; Cancer Care Centre
Kogarah, New South Wales, Australia
- Prince of Wales Hospital; Oncology
Randwick, New South Wales, Australia
- Princess Alexandra Hospital; Division of Cancer Services
Woolloongabba, Queensland, Australia
- Queen Elizabeth Hospital; Medical Oncology
Woodville South, South Australia, Australia
- Western Hospital
Footscray, Victoria, Australia
- Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
- Cabrini Medical Centre; Oncology
Malvern, Victoria, Australia
- Royal Perth Hospital; Department of Medical Oncology
Perth, Western Australia, Australia
- University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
- Clinic of Oncology, University Clinical Center Sarajevo
Sarajevo, Bosnia and Herzegovina
- Centro de Oncologia Da Bahia - Cenob
Salvador, Estado de Bahia, Brazil
- Hospital Sao Rafael - Hsr
Salvador, Estado de Bahia, Brazil
- Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
- Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
- Hospital Perola Byington
São Paulo, São Paulo, Brazil
- Instituto Do Cancer Do Estado de Sao Paulo - Icesp
São Paulo, São Paulo, Brazil
- Complex Oncology Center - Plovdiv First Internal Chemotherapy Department
Plovdiv, Bulgaria
- Mhat Serdika; Department of Medical Oncology
Sofia, Bulgaria
- Shatod - Sofia
Sofia, Bulgaria
- Cross Cancer Institute ; Dept of Medical Oncology
Edmonton, Alberta, Canada
- British Columbia Cancer Agency (bcca) - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
- the Moncton Hospital
Moncton, New Brunswick, Canada
- Lakeridge Health Oshawa; Oncology
Oshawa, Ontario, Canada
- St. Michael'S Hospital
Toronto, Ontario, Canada
- Windsor Regional Cancer Centre
Windsor, Ontario, Canada
- Csss Champlain - Charles-Le Moyne
Greenfield Park, Quebec, Canada
- Mcgill University - Royal Victoria Hospital; Oncology
Montreal, Quebec, Canada
- Centro Oncológico Antofagasta
Antofagasta, Chile
- Instituto Nacional del Cancer
Santiago, Chile
- Sociedad de Investigaciones Medicas Ltda (sim)
Temuco, Chile
- Hospital Carlos Van Buren, Servicio de Oncologia
Valparaíso, Chile
- Clinica del Country
Bogotá, Colombia
- Clínica Imbanaco; Oncology
Cali, Colombia
- Clinical Hospital Osijek; Dept for Oncology & Radiotherapy
Osijek, Croatia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 May 2012
- Primary completion
- 10 Mar 2015
- Completion
- 19 Feb 2020
- Last update posted
- 27 Apr 2021
- Registered enrollment
- 2,577
- Registry id
- NCT01566721
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.